drugset
Drugs / BMS-986120
last change Jun 2022 re-read 2 minutes ago

BMS-986120

also known as BMS-986120-01
Developed for
thrombotic disease
Investigated by
Bristol-Myers Squibb

Trials 1 · a red edge is where a trial was stopped

today NCT02208882 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02208882 Aug 2014 → Feb 2015 — Bristol-Myers Squibb Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02439190 Comparator Sep 2015 → Mar 2016 thrombotic disease Bristol-Myers Squibb Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as BMS-986120 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02208882 ↗
1

NCT02439190 ↗
Known as BMS-986120-01 ChEMBL registry synonym — accepted as the source's own label CHEMBL4650381 ↗
Action Inhibit “BMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) antagonist exhibiting robust antithrombotic activity that has shown low bleeding risk in monkeys.” PMID 35758258 ↗ Jun 2022
Route Oral “multiple oral doses of BMS-986120” NCT02208882 ↗